ArticleAnnals of hematology2026
Population-Based analysis of conditional survival patterns and dynamic prognostic modeling in primary urinary tract lymphoma.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary urinary tract lymphoma (PUTL) is a rare subtype of extranodal lymphoma, with current knowledge largely limited to case reports and small series. This study aimed to evaluate the dynamic survival patterns of PUTL using conditional survival (CS) analysis and to develop a prognostic nomogram for individualized survival prediction.
methodsPatients diagnosed with PUTL between 2000 and 2021 were identified from the SEER database. CS estimates and annual hazard rates were calculated to assess time-dependent changes in survival probability and risk of death. A prognostic model was constructed using variables selected by Random Survival Forest (RSF) and multivariate Cox regression. A CS-nomogram was developed and validated to predict 3-, 5-, and 10-year overall survival (OS) and 10-year conditional survival.
resultsA total of 1,201 patients were included. CS analysis showed that long-term survival probabilities improved significantly with each additional year survived. The highest mortality risk occurred in the first year after diagnosis, followed by a rapid decline and stabilization after three years. Factors such as age, tumor histology, stage, and treatment modalities were identified as significant predictors of OS. The CS-nomogram demonstrated good calibration and discrimination, with AUCs of 0.740, 0.733, and 0.800 for 3-, 5-, and 10-year OS in the training set, and 0.712, 0.708, and 0.794 in the validation set, respectively. Decision curve analysis indicated favorable clinical utility.
conclusionThis study provides the most comprehensive dynamic survival assessment of PUTL to date. CS analysis revealed a favorable shift in prognosis over time, particularly for patients who survived the high-risk early phase. The CS-nomogram enables personalized, time-updated prognostic estimates, supporting more accurate counseling, follow-up planning, and resource optimization in this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.